Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency

Patients affected by primary immunodeficiencies are characterized for high susceptibility for severe infections. Our data demonstrate Kedrion 5% intravenous immunoglobulin G (IVIg) treatment effective and safe as replacement therapy for children and adolescents affected by primary immunodeficiency....

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Silvia, Lippi, Francesca, Canessa, Clementina, Guarnieri, Chiara, Macchia, Roberta, Azzari, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493272/
https://www.ncbi.nlm.nih.gov/pubmed/32924667
http://dx.doi.org/10.1177/2058738420943006
_version_ 1783582533488738304
author Ricci, Silvia
Lippi, Francesca
Canessa, Clementina
Guarnieri, Chiara
Macchia, Roberta
Azzari, Chiara
author_facet Ricci, Silvia
Lippi, Francesca
Canessa, Clementina
Guarnieri, Chiara
Macchia, Roberta
Azzari, Chiara
author_sort Ricci, Silvia
collection PubMed
description Patients affected by primary immunodeficiencies are characterized for high susceptibility for severe infections. Our data demonstrate Kedrion 5% intravenous immunoglobulin G (IVIg) treatment effective and safe as replacement therapy for children and adolescents affected by primary immunodeficiency. The particularities of our study are the selection of a long period of follow-up (71 patient-years of follow-up), and to the best of our knowledge, our study is one of few that assesses the safety and efficacy of intravenous immunoglobulin treatment of primary immunodeficiency specifically in a pediatric population.
format Online
Article
Text
id pubmed-7493272
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74932722020-09-23 Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency Ricci, Silvia Lippi, Francesca Canessa, Clementina Guarnieri, Chiara Macchia, Roberta Azzari, Chiara Int J Immunopathol Pharmacol Original Research Article Patients affected by primary immunodeficiencies are characterized for high susceptibility for severe infections. Our data demonstrate Kedrion 5% intravenous immunoglobulin G (IVIg) treatment effective and safe as replacement therapy for children and adolescents affected by primary immunodeficiency. The particularities of our study are the selection of a long period of follow-up (71 patient-years of follow-up), and to the best of our knowledge, our study is one of few that assesses the safety and efficacy of intravenous immunoglobulin treatment of primary immunodeficiency specifically in a pediatric population. SAGE Publications 2020-09-14 /pmc/articles/PMC7493272/ /pubmed/32924667 http://dx.doi.org/10.1177/2058738420943006 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Ricci, Silvia
Lippi, Francesca
Canessa, Clementina
Guarnieri, Chiara
Macchia, Roberta
Azzari, Chiara
Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
title Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
title_full Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
title_fullStr Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
title_full_unstemmed Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
title_short Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
title_sort efficacy and safety of human intravenous immunoglobulin 5% (ig vena) in pediatric patients affected by primary immunodeficiency
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493272/
https://www.ncbi.nlm.nih.gov/pubmed/32924667
http://dx.doi.org/10.1177/2058738420943006
work_keys_str_mv AT riccisilvia efficacyandsafetyofhumanintravenousimmunoglobulin5igvenainpediatricpatientsaffectedbyprimaryimmunodeficiency
AT lippifrancesca efficacyandsafetyofhumanintravenousimmunoglobulin5igvenainpediatricpatientsaffectedbyprimaryimmunodeficiency
AT canessaclementina efficacyandsafetyofhumanintravenousimmunoglobulin5igvenainpediatricpatientsaffectedbyprimaryimmunodeficiency
AT guarnierichiara efficacyandsafetyofhumanintravenousimmunoglobulin5igvenainpediatricpatientsaffectedbyprimaryimmunodeficiency
AT macchiaroberta efficacyandsafetyofhumanintravenousimmunoglobulin5igvenainpediatricpatientsaffectedbyprimaryimmunodeficiency
AT azzarichiara efficacyandsafetyofhumanintravenousimmunoglobulin5igvenainpediatricpatientsaffectedbyprimaryimmunodeficiency

Ejemplares similares